Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 1

Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factorkappa B (NF-κB) pathway

Pages
368–374
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results of the present study suggest that lycopene and concurrent cisplatin chemotherapy might have a role in improving the treatment of cervical cancer.Key words: Lycopene, cervix cancer, cancer treatment, chemotherapy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Lycopene is associated with anticancer effects in various tumor types.
📊
Key Findings & Data:Materials and methods: HeLa cells were treated with cisplatin (1 µM) alone, lycopene (10 µM) alone, and in combination for 72 h.
💡
Conclusion & Impact:The results of the present study suggest that lycopene and concurrent cisplatin chemotherapy might have a role in improving the treatment of cervical cancer.Key words: Lycopene, cervix cancer, cancer treatment, chemotherapy
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Lycopene is associated with anticancer effects in various tumor types. However, the exact underlying mechanisms of action of lycopene in human cervical cancer remain to be determined. This study aimed to determine anticancer efficacy and mechanism of lycopene in human cervical carcinoma (HeLa) cells. Materials and methods: HeLa cells were treated with cisplatin (1 µM) alone, lycopene (10 µM) alone, and in combination for 72 h. The cell viability of HeLa cells was assessed via MTS assay. Western blot was used to analyze the expression levels of the nuclear factor-kappa B (NF-κB), B-cell-associated X protein (Bax), nuclear factor erythroid 2-related factor (Nrf2), and B-cell lymphoma 2 (Bcl-2). Results: We found that lycopene acts as a synergistic agent with cisplatin in preventing the growth of HeLa cells. The rates of HeLa cells’ viability were 65.6% and 71.1% with lycopene and cisplatin treatment alone compared to the control group, respectively (P < 0.001). The inhibitory effect of cisplatin was enhanced with lycopene addition by declining the cell viability to 37.4% (P < 0.0001). Lycopene treatment significantly increased Bax expression (P < 0.0001) and decreased Bcl-2 expression (P < 0.0001) in HeLa cells. Furthermore, lycopene markedly activated the Nrf2 expression (P < 0.001) and suppressed the NF-κB signaling pathway (P < 0.0001). Conclusion: Lycopene increases the sensitization of cervical cancer cells to cisplatin via inhibition of cell viability, up-regulation of Bax expression, and down-regulation of Bcl-2 expression. Furthermore, the anticancer effect of lycopene might be also associated with suppression of NF-κB-mediated inflammatory responses, and modulation of Nrf2-mediated oxidative stress. The results of the present study suggest that lycopene and concurrent cisplatin chemotherapy might have a role in improving the treatment of cervical cancer.Key words: Lycopene, cervix cancer, cancer treatment, chemotherapy

🔖

Cite This Article

YALÇIN, Ş., GÜNER, G., ŞAHİN, T. K., AKTEPE, O. H., ARIK, Z. (2022). Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factorkappa B (NF-κB) pathway. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 1, 368–374. https://ajindex.com/articles/609537

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians 2019
  2. 69 (1): 7-34. doi: 10.3322/ caac.21551 2. Thaxton L, Waxman AG. Cervical cancer prevention: immunization and screening 2015. Medical Clinics of North America 2015
  3. 99 (3): 469-77. doi: 10.1016/j.mcna.2015.01.003 3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018
  4. 68 (6): 394-424. doi: 10.3322/caac.21492 4. Tewari KS, Sill MW, Long III HJ, Penson RT, Huang H et al. Improved survival with bevacizumab in advanced cervical cancer. The New England Journal of Medicine 2014
  5. 370 (8): 734-43. doi: 10.1056/NEJMoa1309748 5. Zhu H, Luo H, Zhang W, Shen Z, Hu X et al. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development, and Therapy 2016
  6. doi: 10.2147/DDDT.S106412 6. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nature Reviews Cancer 2005
  7. 5 (4): 297. doi: 10.1038/nrc1588 7. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine & Growth Factor Reviews 2010
  8. 21 (1): 11-9. doi: 10.1016/j. cytogfr.2009.11.005 8. Tilborghs S, Corthouts J, Verhoeven Y, Arias D, Rolfo C et al. The role of nuclear factor-kappa B signaling in human cervical cancer. Critical Reviews in Oncology/Hematology 2017
  9. doi: 10.1016/j.critrevonc.2017.11.001 9. Godwin P, Baird A-M, Heavey S, Barr M, O’Byrne K et al. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Frontiers in Oncology 2013
  10. 3 (16): 120. doi: 10.3389/fonc.2013.00120 10. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who’s listening? Antioxidants & Redox Signaling 2010
  11. 13 (11): 1649-63. doi: 10.1089/ars.2010.3216 11. Lee J-M, Li J, Johnson DA, Stein TD, Kraft AD et al. Nrf2, a multi-organ protector? The FASEB Journal 2005
  12. 19 (9): 1061- 6. doi: 10.1096/fj.04-2591hyp 12. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NFκB as the matchmaker. Nature Immunology 2011
  13. 12 (8): 715. doi: 10.1038/ni.2060 13. Chen J, Pu Z, Xiao Y, Li C, Du X et al. Lycopene synthesis via tri-cistronic expression of LeGGPS2, LePSY1 and crtI in Escherichia coli. Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology 2012
  14. 28 (7): 823-33 14. Zu K, Mucci L, Rosner BA, Clinton SK,